Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090050 · ClinicalTrials.gov registry record · Phase 4
Treximet in the Treatment of Chronic Migraine
A Phase 4 study, sponsored by Cady, Roger, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 56
- Enrollment target
NCT01090050 is a Phase 4 study that has completed, run by Cady, Roger, M.D.. The registered enrollment target is 56 participants.
The verdict
NCT01090050, a Phase 4 study, has completed, sponsored by Cady, Roger, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 56 participants
- Enrollment target
Study Summary
This study is being conducted to evaluate the hypothesis that use of Treximet in patients with chronic migraine, when used on a short term daily basis and as rescue for break through attacks, will reduce migraine frequency and impact.
Interventions
- DRUG Naproxen Sodium
- DRUG Sumatriptan/Naproxen Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01090050
The ClinicalTrials.gov registry entry for NCT01090050 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cady, Roger, M.D., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naproxen Sodium is the first listed.
NCT01090050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01090050 about?
NCT01090050 is a clinical study titled "Treximet in the Treatment of Chronic Migraine". This study is being conducted to evaluate the hypothesis that use of Treximet in patients with chronic migraine, when used on a short term daily basis and as rescue for break through attacks, will reduce migraine frequency and impact.
What is the current status of trial NCT01090050?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 56 participants. The study started on 2010-09. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01090050?
The interventions under investigation include: Naproxen Sodium (DRUG), Sumatriptan/Naproxen Sodium (DRUG).
Who is sponsoring clinical trial NCT01090050?
This trial is sponsored by Cady, Roger, M.D., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.